Skip to content
Screener

Net Income at other companies

Eli Lilly logo
Eli LillyLLY
$7.1B+25.3%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$1.1B+6.5%
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
-$106.63M-5.3%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
-$122.93M+9.6%
Beam Therapeutics logo
Beam TherapeuticsBEAM
-$94.32M+12.9%
Regenxbio logo
RegenxbioRGNX
$22.71M+132%

Segments

By segment

See full
Reportable Segment-$42.11M+19.9%

Other financials

Income statement

See full
Revenue$838.0K-61.6%
Operating income-$43.3M+18.9%
EPS (diluted)-$0.24+41.5%

Balance sheet

See full
Cash & equivalents$61.1M-9.4%
Total debt$112.5M-6.1%
Total equity$39.8M-34.6%
Total assets$249.0M-10.7%

Cash flow

See full
Operating cash flow-$41.0M+0.9%
CapEx$46.0K-97.1%
Free cash flow-$41.1M+4.4%

Valuation

See full
Market cap$558.64M-10.7%
Enterprise value$609.98M-10.0%

Profitability

See full
Operating margin-4,498.1%-1,134pp
Net margin-4,342.4%-1,099pp
FCF margin-3,607.4%

Returns & leverage

See full
Return on equity-373.3%-1,281pp
Debt / equity2.8×+0.9×
Current ratio3.1×-0.5×

Where this comes from

Reported directly by Prime Medicine in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The source filing: Prime Medicine’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 8:03 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053883
(in thousands, except share and per share amounts)Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Total other income, net1,1767862,7081,288
Net loss attributable to common stockholders$(42,109)$(52,591)$(91,231)$(104,481)
Net loss per share attributable to common stockholders, basic and diluted$(0.24)$(0.41)$(0.51)$(0.81)
Weighted-average common shares outstanding, basic and diluted177,224,892129,185,918177,160,914128,439,349
Comprehensive loss:
Net loss$(42,109)$(52,591)$(91,231)$(104,481)
Change in unrealized (loss) income on investments, net of tax(8)5(91)(11)
Comprehensive loss$(42,117)$(52,586)$(91,322)$(104,492)

Item 1. Financial Statements (unaudited)

FAQ

What is Prime Medicine's net income?
Prime Medicine (PRME) reported net income of -$42.11M in Q2 2026.
How has Prime Medicine's net income changed year-over-year?
Prime Medicine's net income increased by 19.9% year-over-year, from -$52.59M to -$42.11M.
What is the long-term trend for Prime Medicine's net income?
Over 4 years (2021 to 2025), Prime Medicine's net income has grown at a 5.0% compound annual growth rate (CAGR), from -$165.37M to -$201.14M.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.

Ask your AI about Prime Medicine's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude